m3SMA20

General

Cell Line

hPSCreg name ICGi006-B
Cite as:
ICGi006-B (RRID:CVCL_UF68)
Alternative name(s)
m3SMA20
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
Last update 29th November 2019
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences (ICG)
Owner Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences (ICG)
Distributors
Derivation country Russia

External Databases

BioSamples SAMEA5131666
Cellosaurus CVCL_UF68
Wikidata Q94313415

General Information

Publications
* Is the cell line readily obtainable for third parties?
Yes
Research use: allowed
Clinical use: not allowed
Commercial use: not allowed

Donor Information

General Donor Information

Sex male
Ethnicity Caucasian

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
The donor is a carrier of a disease-associated mutation and affected.
Synonyms
  • SMA type II
  • Intermediate spinal muscular atrophy
  • SMA-II
  • SMA2
  • SMA type 2
show more synonyms

Karyotyping (Donor)

Has the donor karyotype been analysed?
Unknown

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

Donor Relations

Other cell lines of this donor

External Databases (Donor)

BioSamples SAMEA5131665

Ethics

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? Yes
Do you (Depositor/Provider) hold the original Donor Consent Form? Yes
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. pseudonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Does consent expressly prevent the derivation of pluripotent stem cells? No
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No
How may genetic information associated with the cell line be accessed? Controlled Access
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? the D.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology ethics committee
Approval number 65/2014
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? Yes
Name of accrediting authority involved? the D.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology ethics committee
Approval number 65/2014
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?

hIPSC Derivation

General

Source cell line name m3SMA
Derived from same source line (potentially other lot and donor, see below):
Source cell type
A connective tissue cell which secretes an extracellular matrix rich in collagen and other macromolecules. Flattened and irregular in outline with branching processes; appear fusiform or spindle-shaped.; These cells may be vimentin-positive, fibronectin-positive, fsp1-positive, MMP-1-positive, collagen I-positive, collagen III-positive, and alpha-SMA-negative.
Source cell origin
Any skin fibroblast that is part of some dermis.
Collected in 2014

Reprogramming method

Vector type Non-integrating
Vector Episomal
Genes
Is reprogramming vector detectable?
No
Methods used
PCR
Files and images showing reprogramming vector expressed or silenced

Vector free reprogramming

Other

Selection criteria for clones ES-like morphology
Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions

Surface coating Gelatin
Feeder cells
Yes
Passage method Enzymatically
TrypLE
CO2 Concentration 5 %
Medium Other medium:
Base medium: KO-DMEM
Main protein source: Knock-out serum replacement
Serum concentration: 15 %
Supplements
NEAA 0.1 mM
L-glutamine 2 mM
2-Mercaptoethanol 0.25 mM
penicillin 100 U/ml
streptomycin 100 µg/ml
bFGF 10 ng/ml
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
POU5F1 (OCT-4)
Yes
NANOG
Yes
SOX2
Yes
SSEA-4
Yes
TRA 1-81
Yes
Morphology pictures
m3SMA20.tif
Scale bar 500 µm
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro spontaneous differentiation
Marker Expressed
CK18
Yes
Morphology
Mesoderm
Ont Id: UBERON_0000926
In vitro spontaneous differentiation
Marker Expressed
ACTA2
Yes
Morphology
Ectoderm
Ont Id: UBERON_0000924
In vitro spontaneous differentiation
Marker Expressed
TUBB3
Yes
Morphology

Microbiology / Virus Screening

Mycoplasma Negative

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46,XY
Karyotyping method: G-Banding

Other Genotyping (Cell Line)